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The paraoxonase (PON) group of enzymes, composed of PON1, PON2, and PON3, play an important role in decreasing oxidative
stress by degrading lipid peroxides. PON1 synthesis is upregulated by PPAR. Several pharmacological compounds (acting as
antioxidants and, hence, atheroprotective) stimulate both PPAR activity and PON1 expression. Recent evidence suggests that
PON1andthemonocyte chemoattractant protein-1(MCP-1)areinvolved incoordinatingtheinﬂammatoryresponseindamaged
tissues; PPAR may be central in the regulation of these biochemical pathways. This article reviews the state of knowledge on
PON1 biochemistry and function, the inﬂuence of genetic variation, and the regulation of PON1 expression by pharmaceutical
compounds that increase PPAR activity. We also describe recent lines of evidence suggesting links between PON1 and MCP-1 and
how their production may be regulated by PPAR.
1.Introduction
Nuclear receptors are a large group of transcription factors
which are important as master regulators of genes involved
in metabolic control. Hence, an intensive search for ligands
for these receptors is underway so as to design improved
preventive and therapeutic strategies that target these lig-
ands/receptors in an eﬀort to combat diseases which are
direct determinants of the human lifespan. Among these
receptors are the peroxisome proliferator-activated receptors
(PPARs). The name is confusing because they do not induce
proliferation of peroxisomes in humans, but which has been
described in rodents [1]. When this receptor was cloned,
it was termed PPARα [2]. PPARβ/δ and γ were identiﬁed
subsequently as structural homologues of PPARα,w h i c h
were shown to control the expression of other metabolic
genes. The PPAR subfamily of nuclear receptors all bind as
heterodimers with RXR to peroxisome proliferator response
elements in the target gene, especially those involved in the
homeostaticcontrolofmetabolismandinthedefenseagainst
toxiccompounds.Ofparticularimportanceistheassociation
of these receptors with the risk of cancer, cardiovascular
diseases, diabetes and dementia, as well as inﬂammation
and oxidative stress responses that underlie these diseases.
In this scenario, it is relevant to review the relationships
between PPAR and the antioxidant enzymes collectively
termed paraoxonases (PONs).
2.The ParaoxonasesandLipid
PeroxideDegradation
The PON protein family comprises 3 enzymes, PON1,
PON2, and PON3 genes coding which are located close
to each other on chromosome 7q21-22 [3, 4]. PON1
and PON3 genes are expressed in most tissues, and their
protein products are found in circulation bound to high-
density lipoprotein (HDL) [5–7]. Conversely, PON2 is an
intracellularenzymewhichisnotfoundinplasma[8].PON1
wasﬁrstidentiﬁedbyAldridgein1953who,whileexamining
the rates of hydrolysis of organophosphate insecticides in
diﬀerent tissues of rats and rabbits [9, 10], observed that
rabbits had a very high rate of paraoxon degradation in
serum, and that this compound was cleaved by an esterase.2 PPAR Research
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Figure 1: Schematic representation of the most prevalent polymorphisms of the PON1, PON2, and PON3 genes.
Aldridge segregated esterases into two categories according
to whether they were inhibited by interaction with substrates
(B-esterases) or whether they could hydrolyze substrates (A-
esterases). Based on these original publications, the serum
A - e s t e r a s ew a sr e f e r r e dt oa sp a r a o x o n a s eb e c a u s eo fi t s
ability to hydrolyze the toxic oxon metabolite of parathion,
hence “paraoxon”. When two closely similar enzymes were
identiﬁed in the mid-1990s, the original paraoxonase was
referred to as to PON1, while the two new enzymes were
termed PON2 and PON3 [3].
The ability to hydrolyze paraoxon was employed in the
1960s as the method to measure PON1 activity in several
species and tissues. It soon became apparent that, in human
serum, there was considerable variability between individ-
uals with respect to PON1 activity. Frequency distribution
histograms found three diﬀerent phenotypes, corresponding
to high, intermediate, and low serum PON1 activities. Also,
the frequency for the low activity allele varied signiﬁcantly
between populations of diﬀerent geographical or ethnic
origin, a higher frequency being observed in Caucasian than
in African, Asian, or Australian aborigine populations [11].
Over subsequent years, several assays were developed to
examine the PON1 phenotype polymorphism [12]. Plotting
the values of hydrolysis of one substrate (whether phenyl
acetate, diazoxon, or sarin) against that of a second substrate
(paraoxon) provided a clear resolution of the individuals
with low (termed AA), intermediate (termed AB), and high
(termed BB) PON1 activities [13]. Eckerson et al. [14, 15]
noted that the B isozyme was more active in the presence
of NaCl. Using this property, the authors plotted arylesterase
activity values against paraoxonase activity values measured
in the presence of 1M NaCl. This system was shown to be
the most eﬃcient in diﬀerentiating between diﬀerent PON1
polymorphisms.
The genetic bases of PON1 phenotype polymorphisms
were ﬁrst deﬁned by Adkins et al. [16] who sequenced the
coding region for PON1 from human cDNA libraries and
identiﬁed two polymorphic sites: Arg/Gln at position 192
(PON1192 polymorphism, with two alleles termed Q and
R), and Leu/Met at position 55 (PON155 polymorphism,
with two alleles termed L and M). PON1192 polymorphism
correlated clearly with the AB phenotype system, QQ
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Figure 2: The antioxidant role of PON1. The main physiological
role of this enzyme is to degrade oxidized phospholipids and
oxidized cholesteryl esters in lipoproteins.
individuals segregated with the AA phenotype while RR
individuals segregated with the BB phenotype.
In 1997, Blatter Garin et al. [17] evaluated the inﬂuence
of PON1192 and PON155 polymorphisms on the enzyme’s
activity as well as its concentration. They observed consider-
able diﬀerences in relation to PON155 genotype, individuals
carrying a leucine at position 44 (L isoform) having higher
serum PON1 concentrations than those with a methionine
(M isoform) at this position. In contrast, the PON1192
polymorphism aﬀected enzymatic activity but had only a
slight impact on the concentration of PON1 in serum.
These ﬁndings suggested a possible divergence between
the enzyme’s concentration and that of its activity. More
recently, several polymorphisms in the promoter region of
the PON1 gene have been described (Figure 1). However,
only PON1−108, PON1−909, and PON1−1741 appear to be
signiﬁcantlyassociatedwithchangesintheenzyme’sconcen-
tration or activity in serum.
The ﬁrst approximation to the possible physiological role
of PON1 came from experiments by Mackness et al. [18].
Since paraoxon and other toxic chemicals are clearly not
present in the human body under normal circumstances,
other molecules would need to be the physiological sub-
strates of this enzyme. These authors investigated, using
puriﬁed PON1, the protection against copper-induced oxi-
dation of low-density lipoprotein (LDL) that is provided
by HDL (Figure 2). They observed that HDL as well as
PON1 prevented lipoperoxide generation during the process
of LDL oxidation. This implied that the enzyme itselfPPAR Research 3
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Figure 3: The protective role of PON1 in atherosclerosis. Circulating monocytes are activated in an oxidant and inﬂammatory environment
and become macrophages. This environment also promotes the oxidation of LDL particles, which are internalized into the macrophages
that become foam cells. PON1 hydrolyzes oxidized lipids in LDL, reversing this lipoprotein to its natural status and, thus, inhibiting the
development of atherosclerosis. PON1, by inhibiting the production of MCP-1, is anti-inﬂammatory and favors cholesterol eﬄux from
macrophages.
may be involved in the protective function attributed to
HDL. Further studies provided evidence that PON1 pro-
tects LDL and HDL from lipid peroxidation by degrading
speciﬁc oxidized cholesteryl esters and speciﬁc oxidized
phospholipids contained in oxidized lipoproteins [19–25].
Experimental animal studies provided further support to the
in vitro experiments, the data showing that the physiological
function of PON1 is to hydrolyze oxidized lipids and, hence,
function as an antioxidant enzyme. Decreased serum PON1
activities and increased oxidative stress were observed in
apolipoprotein E-deﬁcient mice as well as in dyslipidemic
obese mice [26]. Perhaps the most conclusive data were gen-
erated in the PON1-deﬁcient mouse model and the human-
PON1 transgenic mouse model, PON1 plus apolipopro-
tein E double-deﬁcient mice showing increased lipoprotein
oxidation and atherosclerosis than the apolipoprotein E-
alone deﬁcient mice. HDL isolated from PON1-deﬁcient
mice was unable to prevent LDL oxidation in cultured
arterial tissue, in contrast to HDL obtained from control
mice. Avian HDL (the lipoprotein does not contain PON1)
is unable to protect LDL from oxidation. In agreement
with these observations, overexpression of human PON1 in
transgenic mice inhibited lipid peroxide formation in HDL
andprotectedLDLstructureandfunction[27–30].Ascheme
of the role played by PON1 in protecting against oxidative
stress and atherosclerosis is shown in Figure 3.
PON1 is, in turn, inactivated by oxidized lipids. This
was shown by Aviram et al. [31], who demonstrated
that incubating PON1 in vitro with oxidized palmitoyl
arachidonoyl phosphatidylcholine, lysophosphatidylcholine,
and oxidized cholesteryl arachidonate resulted in inactivated
PON1 arylesterase activity, as well as did oxidized LDL.
Cysteine-284 was required for this eﬀect of oxidized lipids
on PON1 because, in recombinant PON1 in which mutation
of this amino acid had been induced, no inactivation was
observed. Further investigation by the same research group
showed that, under oxidative stress, PON1 may be inacti-
vated by S-glutathionylation, a redox regulatory mechanism
characterized by the formation of a mixed disulﬁde between
a protein thiol (i.e., cysteine-284) and oxidized glutathione
[32].
3.PON1NativeActivityIsLactonase
PON1 hydrolyzes a broad range of substrates including
esters, lactones, organophosphates such as the nerve agents4 PPAR Research
soman and sarin, lipid peroxides, and estrogen esters [12, 13,
33, 34]. In addition, PON1 metabolizes certain drugs and
has been proposed for therapeutic use in drug inactivation
[35, 36]. Identifying the native function of PON1 has
been hampered, for a considerable time, by confusion with
respect to the structure and mechanism-of-action of this
enzyme. Puriﬁed PON1 preparations are unstable and often
contaminated. However, the method of “directed evolution”
has been productive in determining PON1 structure and
function. Essentially, directed evolution seeks to replicate
the evolutionary process in the laboratory by artiﬁcially
inducing mutations in the gene-of-interest, followed by
selection and ampliﬁcation of the variants which show
an enhancement of the desired characteristics. Using this
technique, Harel et al. [37] described PON1 as a six-bladed
beta propeller with a unique active site lid that is also
involved in HDL binding. The active site and the deduced
catalytic mechanism suggested that PON1 is reminiscent
of the secreted phospholipase A2. Despite huge increase in
complexity of living organisms during evolution, relatively
little novelty has been produced at the molecular level
since primordial times [38]. PONs appeared very early
in evolution and are present in many organisms, from
invertebrates to mammals [12]. Jensen [39] proposed that,
incontrasttomoreevolutionary-modernenzymes,primitive
enzymes possessed very broad speciﬁcities, and that it is this
catalytic versatility that enabled a relatively few enzymes to
performthemultitudeoffunctionsnecessarytomaintainthe
ancestral organism [40–43].
Hence,researchonPON1functionwasfocusedontrying
to distinguish the native or “ancestral” function of this
enzyme from all other secondary or “adapted” functions.
Again, directed evolution studies, together with structure-
function studies, established the primordial function of
PON1 as that of a lipolactonase [44–47] which subsequently
evolved new substrate speciﬁcities. These studies also estab-
lished that the preferred substrates of PON1 are 5- and 6-
membered-ring lactones, typically with aliphatic side-chains
[38].
New data on the PON1 mechanism of lactone hydrolysis
have been reported by Tavori et al. [48] using modeling
and docking simulation techniques. These methods use
theoretical models of the ligands being evaluated (in this
case, lactones) which are allowed to interact with models
of the protein’s three-dimensional structure. This enables
the nature of the target ligand, as well as the ﬁtness of the
evaluated ligand within the protein, to be determined. The
authors suggested that PON1 active site may be reached
by a range of lactones that have similar orientation in the
active centre. The carboxylate moiety is directed towards the
hydrophylic inner part of the active centre, while the ligand’s
aromatic ring is facing the outer hydrophobic part. The
results from Tavori et al. also revealed an inverse correlation
between docking energy and rate of lactone hydrolysis, as
well as a direct correlation with the length of lactone side
chain.
Recently, kinetic and site-directed mutagenesis studies
demonstrated that the His115–His134 dyad is necessary for
PON1 lactonase activity and, as well, for oxidized lipid
δ-valerolactone derivatives
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Figure 4: Proposed mechanism for the hydrolysis of oxidized
lipids in macrophages by PON1 to yield lysophosphatidylcholine.
Oxidized lipids with hydroxyl groups at the 5  position could be
lactonized by PON1 to yield lysophosphatidylcholine and the cor-
responding δ-valerolactone products. The latter can be hydrolyzed
again by PON1 to yield the corresponding 5-hydroxycarboxylic
acid.
degradation [49, 50]. A model has been proposed to link
PON1 capability with that of lipid peroxide degradation
[50]. According to this model, oxidized lipids containing
hydroxyl groups at the 5 -position could be lactonized by
PON1 to yield lysophosphatidylcholine and δ-valerolactone
products (Figure 4). As such, according to this hypothesis,
the PON1 ability to degrade lipid peroxides is secondary to
its lipolactonase activity.
4. The Role of PON2 and PON3
Currently, not much is known about PON2 and PON3 pro-
teins.Theirgeneswereidentiﬁedin1996whenPrimo-Parmo
et al. [3] identiﬁed a large number of cDNA sequences in
the Genome Data Base with signiﬁcant homology to, but not
identicalwith,humanPON1.Thepercentageidentityamong
human PON1, PON2, and PON3 genes is similar (about
70%) and the genes are believed to derive from a common
precursor [51]. Ng et al. [8] demonstrated that PON2 is not
present in the circulation, although its gene expression was
detected in several human tissues. The authors concluded
that this represents ubiquitous intracellular distribution of
the enzyme. They also reported that cells transfected with
the human PON2 gene have a higher antioxidant capacity
than those cells that were not transfected. PON3 is present
in HDL and prevents lipoproteins from oxidation in vitro.
PON2 and PON3 also have genetic polymorphisms in theirPPAR Research 5
Table 1: Principal properties of the PON enzymes.
Enzyme Gene expression Protein expression Present in
circulation Lactonase activity Hydrolysis of
lipid peroxides Esterase activity
PON1 Ubiquitous Ubiquitous strong HDL Yes Yes Yes
PON2 Ubiquitous Ubiquitous weak No Yes Yes No
PON3 Ubiquitous Ubiquitous strong HDL Yes Yes No
promoter and codifying regions that inﬂuence their protein
expression (Figure 1). Both PON2 and PON3 are able to
hydrolyze lactones, but not paraoxon or other xenobiotics
[34, 52, 53], that is, all three PON enzymes have lactonase
activity and hydrolyze lipid peroxides, but only PON1 has
esterase activity (Table 1).
5. PON1 and PPARα
Fibrates are hypolipidemic drugs that act via activation
of PPARα. Their main therapeutic function is to decrease
serum triglyceride concentrations. A mild increase in HDL-
cholesterol concentration is also achieved. PPARα activators
induce the expression of apolipoprotein A1, the main
apoprotein of HDL, and of the ATP-binding cassette of
A1 (ABCA1), a transporter complex controlling cellular
cholesterol eﬄux [54].
There have been conﬂicting reports on the inﬂuence of
ﬁbrate therapy on serum PON1 levels. Increase in enzyme
activity appears to depend on type, and perhaps dosage,
of ﬁbrate employed. Durrington et al. [55] observed that
bezaﬁbrate and gemﬁbrozil, administered for 8 weeks, failed
to inﬂuence serum PON1 activity in type IIb hyperlipidemic
patients. Tsimihodimos et al. [56] found that 3-month
treatment with micronized fenoﬁbrate did not inﬂuence
PON1 levels in types IIa, IIb and IV dyslipidemic patients.
Conversely, Paragh et al. [57] observed that a 3-month
administrationofgemﬁbrozilincreasedserumPON1activity
in patients with hypertriglyceridemia. This research group
found that ciproﬁbrate administration increased HDL-
cholesterol concentration and serum PON1 activity in
patients with metabolic syndrome [58]. In rats receiving
a fructose-enriched diet (an experimental model of liver
steatosis and metabolic syndrome), bezaﬁbrate reduced
oxidative stress and increased serum PON1 levels [59]. A
recent report described that micronized ﬁbrate increased
the activity and concentration of PON1 and reduced oxi-
dized LDL levels in dyslipidemic patients with low HDL-
cholesterollevels.Interestingly,thiseﬀectwasindependentof
PON1 gene polymorphisms [60]. There are several potential
PPARα binding sites in the PON1 gene promoter. However,
Gou´ edard et al. [61] did not observe any increase in
PON1 gene expression following PPARα activation, and
this suggested that the mechanism of promoter activation
induced by ﬁbrates does not involve this nuclear receptor.
6. PON1, PON2, andPPARγ
R o s i g l i t a z o n ei saP P A R γ agonist that improves insulin sen-
sitivity and glycemic control, stimulates reverse cholesterol
transport, and reduces inﬂammation in individuals with
type 2 diabetes [62–64]. In a randomized, cross-over,
placebo-controlled, double-blind clinical trial, rosiglitazone
was shown to increase fasting PON1 activity and to
attenuate the postprandial fall in PON1 activity. However,
the concentration of serum PON1 was observed not to
change signiﬁcantly [65]. A combination of rosiglitazone
and metformin improved insulin resistance and fat distri-
bution abnormalities (lipodystrophy) in patients infected
with the human immunodeﬁciency virus (HIV) [66]. Our
group reported that both treatments increased fasting and
post-prandial serum PON1 activity and decreased plasma
concentrations of the monocyte chemoattractant protein-1
(MCP-1) in HIV-infected patients undergoing highly active
antiretroviral therapy [67]. Results from these studies indi-
cated that plasma HDL-cholesterol concentrations did not
signiﬁcantly change. These data suggested that the observed
eﬀects on PON1 were independent of HDL synthesis.
We also reported that metformin activates the peroxisome
proliferators-activated response coactivator-1α and regulates
oxidative stress homeostasis [68].
Several studies have shown that statins, widely used
pharmacological compounds for the treatment of hyperlipi-
demia, activate PPARγ, and that this activation is associated
with increases in PON1 expression. Tom` as et al. [69]
were the ﬁrst to report that simvastatin administration
(20mg/day for 4 months) increased serum PON1 activity
in hypercholesterolemic patients. The increases were modest
(about12%onaverage)andwereaccompaniedbysigniﬁcant
decreases in serum cholesterol and lipid peroxides, as
well as LDL-cholesterol concentrations. They did not ﬁnd
any signiﬁcant modulation associated with HDL-cholesterol
levels or with PON1192 and PON155 DNA polymorphisms.
Simvastatin attenuated myocardial inﬂammation in rats that
had cardiopulmonary bypass surgery, and the phenomenon
was associated with an increase in PPARγ expression [70].
Atorvastatin and rosuvastatin have also been shown to
increase PPARγ [71] and PON1 expressions. Harangi et al.
[72] observed that atorvastatin (10mg/day for 6 months)
increased serum PON1 activity in hypercholesterolemic
patients, with changes in lipid proﬁle and oxidative stress
similar to those described by Tom` as et al. (described
above). Kassai et al. [73] also conﬁrmed that atorvastatin
(20mg/day for 3 months) increased serum PON1 activity.
ThisstatinhasbeenshowntoincreaseserumPON1activities
in experimental rabbits fed a high-cholesterol diet [74].
However, Bergheanu et al. [75] reported that atorvastatin
(increasing doses up to 80mg/day for 18 weeks) did not
modify serum PON1 activity, although rosuvastatin admin-
istration (increasing doses up to 40mg/day for the same6 PPAR Research
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Figure 5: A hypothetical biochemical pathway that could explain the PON1 alterations observed in rats with experimental cirrhosis. Free-
radical-induced liver impairment would result in a decrease in PPARδ gene expression and, as a consequence, in PON1 gene expression.
It would also induce an inhibition of ABCA1, a decrease in HDL synthesis, and, therefore, a decrease in serum PON1 concentration.
Intrahepatic PON1 levels would be increased as a consequence of decreased protein degradation. This ﬁgure is reproduced from [79].
period of time) was associated with a signiﬁcant increase
in serum PON1 activity. A recent detailed clinical report by
Mirdamadi et al. [76] was that of a study conducted with 164
hypercholesterolemic patients subdivided into three groups
to receive atorvastatin (10mg/day, n = 61), simvastatin (10–
20mg/day, n = 46), or ﬂuvastatin (80mg/day, n = 57) for
a period of 3 months. The results indicated that all three
statins were able to increase serum PON1 activity, albeit
moderately.
Of note is the study by Shiner et al. [77] which found
that antioxidant polyphenols obtained from some plants
increased PON1 and PON2 expression through PPARγ acti-
vation. Pomegranate juice and its polyphenols (punicalagin
and gallic acid) increased PON2 expression in cultured
macrophages, and this phenomenon was associated with
activation of PPARγ and AP-1. Similarly, the incubation
of hepatocytes with polyphenols from pomegranate juice
increasedPON1expressionviathePPARγ-PKA-cAMPpath-
way [78].
7. PON1 andPPARδ
Thereisadearthofinformationonthepossiblerelationships
between PPARδ and PON1. Our group reported [79] that
rats with experimental liver cirrhosis had a signiﬁcant
decrease in hepatic PPARδ and PON1 expression which
wasassociatedwithinﬂammatoryandﬁbrogeneticreactions.
However,hepaticPON1proteinconcentrationwasincreased
as a consequence of a decreased degradation of the enzyme
(Figure 5). We did not observe any signiﬁcant change in
PPARα and PPARγ expression. These results suggested an
involvement of PPARδ in the regulation of oxidative stress in
chronic liver impairment. To the best of our knowledge, thisPPAR Research 7
is the only published report showing an association between
this transcription factor and PON1.
8.CombinedFunctioningofPON1 andMCP-1
inRegulatingInﬂammatoryResponse:ARole
for PPAR?
The upregulation of MCP-1 production by oxidized lipids
and lipoproteins is an important factor in the initial stages
of inﬂammation [80, 81]. Mackness et al. [82] demonstrated
that PON1, when incubated with endothelial cells, inhibited
the production of MCP-1 induced by oxidized LDL. Indeed,
several lines of evidence recently published by our group
suggest that PON1 and MCP-1 act collaboratively in reg-
ulating inﬂammatory processes. PON1 and MCP-1 protein
expressions are observed in conjunction in most normal and
diseased tissues, while increased MCP-1 concentration and
decreased PON1 activity are often observed in conditions
involving oxidative stress [7, 83, 84].
Lysophosphatidylcholine (LPC) is a prominent compo-
nent of oxidized LDL. During oxidation, 40% of LDL phos-
phatidylcholine can be converted to LPC by LDL-associated
phospholipase A2. LPC stimulates the cellular production of
MCP-1 at the transcription level through a mechanism that
involves MEK/ERK, tyrosine kinase, and (to a lesser extent)
protein kinase C (PKC) [85]. More recent data suggest
that 12/15-lipoxygenase (12/15LO) is required for early
onsethigh-fat-diet-inducedadiposetissueinﬂammationand
insulin resistance in mice [86]. Cells overexpressing 12/15LO
secrete an excess of MCP-1 and, correspondingly, adipose
tissues from 12/15LO knockout (KO) mice fed a high-fat diet
are not inﬁltrated by macrophages, do not show any increase
in inﬂammatory markers, and do not exhibit changes in
insulin-stimulated glucose disposal rate or of hepatic glucose
output.
An interesting hypothesis is that PPARs are intimately
involved in regulating and coordinating PON1 and MCP-1
expression. Considerable evidence (highlighted here in after)
shows that PPARs upregulate PON1 expression in a variety
of clinical and experimental situations. Recent evidence
indicates that PPAR downregulates MCP-1 expression. Sim-
vastatin decreases serum MCP-1 concentration in rats with
cardiopulmonary bypass surgery and stimulates myocardial
PPARγ levels [70]. Similarly, rosuvastatin and atorvastatin
increases PPAR expression and attenuates atherosclerosis
mice deﬁcient in apolipoprotein E [71] .P r o p o f o l ,as e d a t i v e
with antioxidant properties, decreases oxidative stress and
MCP-1 production and increases PPARγ in mice with sepsis-
induced acute kidney injury [87]. Quercetin attenuates
inﬂammation, decreases MCP-1 production, and improves
insulin resistance in human-cultured adipocytes. This com-
pound also counteracts tumor necrosis factor-induced inhi-
bition of PPARγ expression in these cells [88]. Rosiglitazone,
which is a ligand for PPARγ, inhibits inﬂammation and
reduces MCP-1 production by murine cells [89] and has
similar eﬀects on lipopolysaccharide-treated mice and HK-2
cells [90]. Finally, telmisartan, an angiotensin type I receptor
blocker, increases PPARγ activity and PPAR ligand-binding
activity, reduces atherosclerosis in mouse macrophages [91],
and reduces MCP-1 production by peripheral monocytes in
patients with essential hypertension [92].
9. Conclusion
It seems well established that PPARs, especially PPARγ,a r e
important factors in the regulation of PON1 expression,
and in counteracting oxidative stress. Evidence exists that
they also contribute to the control of inﬂammation by
downregulating the expression of MCP-1. Several pharma-
ceutical preparations eliciting a beneﬁcial antioxidant, anti-
inﬂammatory, and atheroprotective function increase PON1
expression and decrease that of MCP-1. These data suggest
that PPARs play a key role in the regulation of oxidation
and inﬂammation and, as such, drugs that stimulate PPAR
activity may be important tools in the struggle against
diseases related to these biochemical alterations.
Acknowledgments
Some studies described in this article have been funded by
Grants from the Instituto de Salud Carlos III (PI 02/0430, PI
04/1752, PI 05/1607, PI 08/1175, PI 08/1381, RCMN C03/08,
and RD06), Ministerio de Sanidad, Madrid, Spain. Editorial
assistancewasprovidedbyDr.PeterR.Turnerfromt-SciMed
(L’Ametlla de Mar, Spain).
References
[1] J. M. Thorp and W. S. Waring, “Modiﬁcation of metabolism
and distribution of lipids by ethyl chlorophenoxyisobutyrate,”
Nature, vol. 194, no. 4832, pp. 948–949, 1962.
[ 2 ]I .I s s e m a n na n dS .G r e e n ,“ A c t i v a t i o no fam e m b e ro f
the steroid hormone receptor superfamily by peroxisome
proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
[3] S. L. Primo-Parmo, R. C. Sorenson, J. Teiber, and B. N. La Du,
“The human serum paraoxonase/arylesterase gene (PON1)i s
one member of a multigene family,” Genomics,v o l .3 3 ,n o .3 ,
pp. 498–507, 1996.
[4] R. C. Sorenson, S. L. Primo-Parmo, S. A. Camper, and B. N.
La Du, “The genetic mapping and gene structure of mouse
paraoxonase/arylesterase,” Genomics, vol. 30, no. 3, pp. 431–
438, 1995.
[5] L. C. Jaouad, C. de Guise, H. Berrougui et al., “Age-related
decrease in high-density lipoproteins antioxidant activity is
due to an alteration in the PON1’s free sulfhydyl groups,”
Atherosclerosis, vol. 185, no. 1, pp. 191–200, 2006.
[6] I. Leviev, F. Negro, and R. W. James, “Two alleles of the human
p a r a o x o n a s eg e n ep r o d u c ed i ﬀerent amounts of mRNA:
an explanation for diﬀerences in serum concentrations of
paraoxonaseassociatedwiththe(Leu-Met54)polymorphism,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no.
11, pp. 2935–2939, 1997.
[7] F. Rodr´ ıguez-Sanabria, A. Rull, R. Beltr´ an-Deb´ on et al.,
“Tissue distribution and expression of paraoxonases and
chemokines in mouse: the ubiquitous and joint localisation
suggest a systemic and coordinated role,” Journal of Molecular
Histology, vol. 41, no. 6, pp. 379–386, 2010.8 PPAR Research
[8] C.J.Ng,D.J.Wadleigh,A.Gangopadhyayetal.,“Paraoxonase-
2 is a ubiquitously expressed protein with antioxidant prop-
erties and is capable of preventing cell-mediated oxidative
modiﬁcation of low density lipoprotein,” Journal of Biological
Chemistry, vol. 276, no. 48, pp. 44444–44449, 2001.
[9] W. N. Aldridge, “Serum esterases. I. Two types of esterase
(A and B) hydrolysing p-nitrophenyl acetate, propionate
and butyrate, and a method for their determination,” The
Biochemical Journal, vol. 53, no. 1, pp. 110–117, 1953.
[10] W. N. Aldridge, “Serum esterases. II. An enzyme hydrolysing
diethyl p-nitrophenyl phosphate (E600) and its identity with
the A-esterase of mammalian sera,” The Biochemical Journal,
vol. 53, no. 1, pp. 117–124, 1953.
[11] T. L. Diepgen and M. Geldmacher von Mallinckrodt,
“Interethnic diﬀerences in the detoxiﬁcation of organophos-
phates: the human serum paraoxonase polymorphism,”
Archives of Toxicology, vol. 59, no. 9, pp. 154–158, 1986.
[12] C. E. Furlong, “Paraoxonases: an historical perspective,” in
The Paraoxonases: Their Role in Disease Development and
Xenobiotic Metabolism, B. Mackness, M. Mackness, M. Avi-
ram, and G. Paragh, Eds., pp. 3–31, Springer, Dordrecht, The
Netherlands, 2008.
[13] H. Davies, R. J. Richter, M. Keifer, C. Broomﬁeld, J. Sowalla,
and C. E. Furlong, “The eﬀect of the human serum paraox-
onase polymorphism is reversed with diazoxon, soman and
sarin,” Nature Genetics, vol. 14, no. 3, pp. 334–336, 1996.
[14] H. W. Eckerson, J. Romson, C. Wyte, and B. N. La Du, “The
human serum paraoxonase polymorphism: identiﬁcation of
phenotypes by their response to salts,” American Journal of
Human Genetics, vol. 35, no. 2, pp. 214–227, 1983.
[15] H. W. Eckerson, C. M. Wyte, and B. N. La Du, “The human
serum paraoxonase/arylesterase polymorphism,” American
JournalofHumanGenetics,vol.35,no.6,pp.1126–1138,1983.
[16] S. Adkins, K. Gan, M. Mody, and B. N. La Du, “Molecular
basis for the polymorphic forms of human serum paraox-
onase/arylesterase: glutamine or arginine at position 191, for
the respective A or B allozymes,” American Journal of Human
Genetics, vol. 52, no. 3, pp. 598–608, 1993.
[17] M. C. Blatter Garin, R. W. James, P. Dussoix et al., “Paraox-
onase polymorphism Met-Leu54 is associated with modiﬁed
serum concentrations of the enzyme. A possible link between
the paraoxonase gene and increased risk of cardiovascular
disease in diabetes,” Journal of Clinical Investigation, vol. 99,
no. 1, pp. 62–66, 1997.
[18] M. I. Mackness, S. Arrol, and P. N. Durrington, “Paraox-
onase prevents accumulation of lipoperoxides in low-density
lipoprotein,”FEBSLetters,vol.286,no.1-2,pp.152–154,1991.
[19] M. I. Mackness, S. Arrol, C. A. Abbott, and P. N. Durrington,
“Protection of low-density lipoprotein against oxidative mod-
iﬁcation by high-density lipoprotein associated paraoxonase,”
Atherosclerosis, vol. 104, no. 1-2, pp. 129–135, 1993.
[20] M.Navab,J.A.Berliner,A.D.Watsonetal.,“TheYinandYang
of oxidation in the development of the fatty streak: a review
based on the 1994 George Lyman Duﬀ memorial lecture,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no.
7, pp. 831–842, 1996.
[ 2 1 ]M .A v i r a m ,M .R o s e n b l a t ,C .L .B i s g a i e r ,R .S .N e w t o n ,S .L .
Primo-Parmo, and B. N. La Du, “Paraoxonase inhibits high-
density lipoprotein oxidation and preserves its functions: a
possible peroxidative role for paraoxonase,” Journal of Clinical
Investigation, vol. 101, no. 8, pp. 1581–1590, 1998.
[22] M. Aviram, S. Billecke, R. Sorenson et al., “Paraoxonase active
site required for protection against LDL oxidation involves its
free sulfhydryl group and is diﬀerent from that required for its
arylesterase/paraoxonase activities: selective action of human
paraoxonase allozymes Q and R,” Arteriosclerosis, Thrombosis,
and Vascular Biology, vol. 18, no. 10, pp. 1617–1624, 1998.
[23] M. I. Mackness, P. N. Durrington, and B. Mackness, “How
high-density lipoprotein protects against the eﬀects of lipid
peroxidation,” Current Opinion in Lipidology, vol. 11, no. 4,
pp. 383–388, 2000.
[24] Z. Ahmed, A. Ravandi, G. F. Maguire et al., “Apolipoprotein
A-I promotes the formation of phosphatidylcholine core
aldehydesthatarehydrolyzedbyparaoxonase(PON-1)during
highdensitylipoproteinoxidationwithaperoxvnitritedonor,”
Journal of Biological Chemistry, vol. 276, no. 27, pp. 24473–
24481, 2001.
[25] P. Sangvanich, B. Mackness, S. J. Gaskell, P. Durrington, and
M. Mackness, “The eﬀect of high-density lipoproteins on the
formation of lipid/protein conjugates during in vitro oxida-
tion of low-density lipoprotein,” Biochemical and Biophysical
Research Communications, vol. 300, no. 2, pp. 501–506, 2003.
[26] A. Mertens, P. Verhamme, J. K. Bielicki et al., “Increased
low-density lipoprotein oxidation and impaired high-density
lipoprotein antioxidant defense are associated with increased
macrophagehomingandatherosclerosisindyslipidemicobese
mice: LCAT gene transfer decreases atherosclerosis,” Circula-
tion, vol. 107, no. 12, pp. 1640–1646, 2003.
[27] D. M. Shih, L. Gu, Y. R. Xia et al., “Mice lacking serum
paraoxonase are susceptible to organophosphate toxicity and
atherosclerosis,” Nature, vol. 394, no. 6690, pp. 284–287, 1998.
[28] D. M. Shih, Y. R. Xia, E. Miller et al., “Combined
serum paraoxonase knockout/apolipoprotein E knockout
mice exhibit increased lipoprotein oxidation and atheroscle-
rosis,” Journal of Biological Chemistry, vol. 275, no. 23, pp.
17527–17535, 2000.
[29] A. Tward, Y. R. Xia, X. P. Wang et al., “Decreased atheroscle-
rotic lesion formation in human serum paraoxonase trans-
genic mice,” Circulation, vol. 106, no. 4, pp. 484–490, 2002.
[30] M. N. Oda, J. K. Bielicki, T. T. Ho, T. Berger, E. M. Rubin,
and T. M. Forte, “Paraoxonase 1 overexpression in mice
and its eﬀect on high-density lipoproteins,” Biochemical and
Biophysical Research Communications, vol. 290, no. 3, pp. 921–
927, 2002.
[ 3 1 ]M .A v i r a m ,M .R o s e n b l a t ,S .B i l l e c k ee ta l . ,“ H u m a ns e r u m
paraoxonase (PON 1) is inactivated by oxidized low density
lipoprotein and preserved by antioxidants,” Free Radical
Biology and Medicine, vol. 26, no. 7-8, pp. 892–904, 1999.
[32] O. Rozenberg and M. Aviram, “S-Glutathionylation regulates
HDL-associated paraoxonase 1 (PON1) activity,” Biochemical
and Biophysical Research Communications, vol. 351, no. 2, pp.
492–498, 2006.
[33] H. Jakubowski, “Calcium-dependent human serum homocys-
teine thiolactone hydrolase. A protective mechanism against
protein N-homocysteinylation,” Journal of Biological Chem-
istry, vol. 275, no. 6, pp. 3957–3962, 2000.
[34] J. F. Teiber, D. I. Draganov, and B. N. La Du, “Lactonase and
lactonizing activities of human serum paraoxonase (PON1)
and rabbit serum PON3,” Biochemical Pharmacology, vol. 66,
no. 6, pp. 887–896, 2003.
[35] K. Biggadike, R. M. Angell, C. M. Burgess et al., “Selective
plasma hydrolysis of glucocorticoid γ-lactones and cyclic
carbonates by the enzyme paraoxonase: an ideal plasma
inactivation mechanism,” Journal of Medicinal Chemistry, vol.
43, no. 1, pp. 19–21, 2000.
[36] B.N.LaDu,M.Aviram,S.Billeckeetal.,“Onthephysiological
role(s) of the paraoxonases,” Chemico-Biological Interactions,
vol. 119-120, pp. 379–388, 1999.PPAR Research 9
[37] M. Harel, A. Aharoni, L. Gaidukov et al., “Structure and
evolution of the serum paraoxonase family of detoxifying
and anti-atherosclerotic enzymes,” Nature Structural and
Molecular Biology, vol. 11, no. 5, pp. 412–419, 2004.
[38] O. Khersonsky, C. Roodveldt, and D. S. Tawﬁk, “Enzyme
promiscuity: evolutionary and mechanistic aspects,” Current
Opinion in Chemical Biology, vol. 10, no. 5, pp. 498–508, 2006.
[39] R. A. Jensen, “Enzyme recruitment in evolution of new
function,”Annual Review of Microbiology,vol.30,pp.409–425,
1976.
[40] U. T. Bornscheuer and R. J. Kazlauskas, “Catalytic promiscuity
in biocatalysis: using old enzymes to form new bonds and
follow new pathways,” Angewandte Chemie, vol. 43, no. 45, pp.
6032–6040, 2004.
[41] S. D. Copley, “Enzymes with extra talents: moonlighting
functions and catalytic promiscuity,” Current Opinion in
Chemical Biology, vol. 7, no. 2, pp. 265–272, 2003.
[42] R. J. Kazlauskas, “Enhancing catalytic promiscuity for bio-
catalysis,” Current Opinion in Chemical Biology, vol. 9, no. 2,
pp. 195–201, 2005.
[43] P. J. O’Brien and D. Herschlag, “Catalytic promiscuity and the
evolution of new enzymatic activities,” Chemistry and Biology,
vol. 6, no. 4, pp. R91–R105, 1999.
[44] A. Aharoni, G. Amitai, K. Bernath, S. Magdassi, and D. S.
Tawﬁk, “High-throughput screening of enzyme libraries: thi-
olactonases evolved by ﬂuorescence-activated sorting of single
cells in emulsion compartments,” Chemistry and Biology, vol.
12, no. 12, pp. 1281–1289, 2005.
[45] A. Aharoni, L. Gaidukov, O. Khersonsky, S. M. Gould, C.
Roodveldt, and D. S. Tawﬁk, “The “evolvability” of promis-
cuous protein functions,” Nature Genetics,v o l .3 7 ,n o .1 ,p p .
73–76, 2005.
[46] A. Aharoni, L. Gaidukov, S. Yagur, L. Toker, I. Silman, and D.
S. Tawﬁk, “Directed evolution of mammalian paraoxonases
PON1 and PON3 for bacterial expression and catalytic
specialization,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 101, no. 2, pp. 482–487,
2004.
[47] O. Khersonsky and D. S. Tawﬁk, “Structure-reactivity studies
of serum paraoxonase PON1 suggest that its native activity is
lactonase,” Biochemistry, vol. 44, no. 16, pp. 6371–6382, 2005.
[48] H.Tavori,S.Khatib,M.Aviram,andJ.Vaya,“Characterization
of the PON1 active site using modeling simulation, in
relation to PON1 lactonase activity,” Bioorganic and Medicinal
Chemistry, vol. 16, no. 15, pp. 7504–7509, 2008.
[49] O. Khersonsky and D. S. Tawﬁk, “The histidine 115-histidine
134 dyad mediates the lactonase activity of mammalian serum
paraoxonases,”JournalofBiologicalChemistry,vol.281,no.11,
pp. 7649–7656, 2006.
[50] M. Rosenblat, L. Gaidukov, O. Khersonsky et al., “The
catalytic histidine dyad of high density lipoprotein-associated
serum paraoxonase-1 (PON1) is essential for PON1-mediated
inhibition of low density lipoprotein oxidation and stimula-
tion of macrophage cholesterol eﬄux,” Journal of Biological
Chemistry, vol. 281, no. 11, pp. 7657–7665, 2006.
[51] N. Bourquard, D. M. Shih, and C. J. Ng et al, “The role of
PON2 and PON3 in atherosclerosis and related trait,” in The
Paraoxonases: Their Role in Disease Development and Xeno-
biotic Metabolism, B. Mackness, M. Mackness, M. Aviram,
and G. Paragh, Eds., pp. 103–128, Springer, Dordrecht, The
Netherlands, 2008.
[52] S. T. Reddy, D. J. Wadleigh, V. Grijalva et al., “Human
paraoxonase-3 is an HDL-associated enzyme with biological
activity similar to paraoxonase-1 protein but is not regulated
by oxidized lipids,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 21, no. 4, pp. 542–547, 2001.
[ 5 3 ]D .D r a g a n o v ,P .L .S t e t s o n ,C .E .W a t s o n ,S .B i l l e c k e ,a n d
B. N. La Du, “Rabbit serum paraoxonase 3 (PON3) is a
high density lipoprotein-associated lactonase and protects low
density lipoprotein against oxidation,” Journal of Biological
Chemistry, vol. 275, no. 43, pp. 33435–33442, 2000.
[54] G. Paragh, M. Harangi, and I. Seres, “Eﬀect of lipid lowering
medications in PON1,” in The Paraoxonases: Their Role in
Disease Development and Xenobiotic Metabolism, B. Mackness,
M. Mackness, M. Aviram, and G. Paragh, Eds., pp. 251–266,
Springer, Dordrecht, The Netherlands, 2008.
[55] P. N. Durrington, M. I. Mackness, D. Bhatnagar et al.,
“Eﬀects of two diﬀerent ﬁbric acid derivatives on lipoproteins,
cholesteryl ester transfer, ﬁbrinogen, plasminogen activator
inhibitor and paraoxonase activity in type IIb hyperlipopro-
teinaemia,” Atherosclerosis, vol. 138, no. 1, pp. 217–225, 1998.
[56] V. Tsimihodimos, A. Kakaﬁka, A. P. Tambaki et al., “Fenoﬁ-
brate induces HDL-associated PAF-AH but attenuates enzyme
activity associated with apoB-containing lipoproteins,” Jour-
nal of Lipid Research, vol. 44, no. 5, pp. 927–934, 2003.
[57] G.Paragh,I.Seres,M.Harangietal.,“Theeﬀectofmicronised
fenoﬁbrate on paraoxonase activity in patients with coronary
heart disease,” Diabetes and Metabolism,v o l .2 9 ,n o .6 ,p p .
613–618, 2003.
[58] G. Paragh, I. Seres, M. Harangi et al., “Ciproﬁbrate increases
paraoxonase activity in patients with metabolic syndrome,”
BritishJournalofClinicalPharmacology,vol.61,no.6,pp.694–
701, 2006.
[59] Z. Ackerman, M. Oron-Herman, T. Rosenthal et al., “Eﬀects
of amlodipine, captopril, and bezaﬁbrate on oxidative milieu
in rats with fatty liver,” Digestive Diseases and Sciences, vol. 53,
no. 3, pp. 777–784, 2008.
[60] W. Phuntuwate, C. Suthisisang, B. Koanantakul, P.
Chaloeiphap, B. Mackness, and M. Mackness, “Eﬀect of
fenoﬁbrate therapy on paraoxonase1 status in patients
with low HDL-C levels,” Atherosclerosis, vol. 196, no. 1, pp.
122–128, 2008.
[61] C. Gou´ edard, N. Koum-Besson, R. Barouki, and Y. Morel,
“Opposite regulation of the human paraoxonase-1 gene PON-
1 by fenoﬁbrate and statins,” Molecular Pharmacology, vol. 63,
no. 4, pp. 945–956, 2003.
[62] P. Raskin, E. B. Rappaport, S. T. Cole, Y. Yan, R. Patwardhan,
and M. I. Freed, “Rosiglitazone short-term monotherapy
lowers fasting and post-prandial glucose in patients with Type
II diabetes,” Diabetologia, vol. 43, no. 3, pp. 278–284, 2000.
[63] J. P. van Wijk, E. J. de Koning, M. C. Cabezas, and T. J.
Rabelink, “Rosiglitazone improves postprandial triglyceride
and free fatty acid metabolism in type 2 diabetes,” Diabetes
Care, vol. 28, no. 4, pp. 844–849, 2005.
[64] B. Chappuis, M. Braun, C. Stettler et al., “Diﬀerential eﬀect
of pioglitazone (PGZ) and rosiglitazone (RGZ) on postpran-
dial glucose and lipid metabolism in patients with type 2
diabetes mellitus: a prospective, randomized crossover study,”
Diabetes/Metabolism Research and Reviews, vol. 23, no. 5, pp.
392–399, 2007.
[65] J. van Wijk, B. Coll, M. C. Cabezas et al., “Rosiglitazone mod-
ulates fasting and post-prandial paraoxonase 1 activity in type
2 diabetic patients,” Clinical and Experimental Pharmacology
and Physiology, vol. 33, no. 12, pp. 1134–1137, 2006.
[66] K. Mulligan, Y. Yang, D. A. Wininger et al., “Eﬀects of
metformin and rosiglitazone in HIV-infected patients with
hyperinsulinemia and elevated waist/hip ratio,” AIDS, vol. 21,
no. 1, pp. 47–57, 2007.10 PPAR Research
[67] B.Coll,J.P.H.vanWijk,S.Parraetal.,“Eﬀectsofrosiglitazone
and metformin on postprandial paraoxonase-1 and mono-
cyte chemoattractant protein-1 in human immunodeﬁciency
virus-infected patients with lipodystrophy,” European Journal
of Pharmacology, vol. 544, no. 1–3, pp. 104–110, 2006.
[68] J. A. Menendez, S. Cuf´ ı, C. Oliveras-Ferraros, L. Vellon, J.
Joven, and A. Vazquez-Martin, “Gerosuppressant metformin:
less is more,” Aging, vol. 3, no. 4, pp. 348–362, 2011.
[69] M. Tom´ a s ,M .S e n t ´ ı, F. Garc´ ıa-Faria et al., “Eﬀe c to fs i m v a s -
tatin therapy on paraoxonase activity and related lipoproteins
in familial hypercholesterolemic patients,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 20, no. 9, pp. 2113–
2119, 2000.
[70] Y. Shen, H. Wu, C. Wang et al., “Simvastatin attenuates
cardiopulmonary bypass-induced myocardial inﬂammatory
injury in rats by activating peroxisome proliferator-activated
receptor γ,” European Journal of Pharmacology, vol. 649, no.
1–3, pp. 255–262, 2010.
[71] J. A. Wang, W. A. Chen, Y. Wang et al., “Statins exert diﬀer-
ential eﬀects on angiotensin II-induced atherosclerosis, but no
beneﬁt for abdominal aortic aneurysms,” Atherosclerosis, vol.
217, no. 1, pp. 90–96, 2011.
[72] M. Harangi, I. Seres, Z. Varga et al., “Atorvastatin eﬀect
on high-density lipoprotein-associated paraoxonase activity
and oxidative DNA damage,” European Journal of Clinical
Pharmacology, vol. 60, no. 10, pp. 685–691, 2004.
[73] A. Kassai, L. Illy´ es, H. Z. Mirdamadi et al., “The eﬀect of
atorvastatin therapy on lecithin: cholesterol acyltransferase,
cholesteryl ester transfer protein and the antioxidant paraox-
onase,” Clinical Biochemistry, vol. 40, no. 1-2, pp. 1–5, 2007.
[74] I. M. Bolayirli, M. Aslan, H. Balci, T. Altug, M. Hacibekiroglu,
a n dA .S e v e n ,“ E ﬀects of atorvastatin therapy on hypercholes-
terolemic rabbits with respect to oxidative stress, nitric oxide
pathway and homocysteine,” Life Sciences, vol. 81, no. 2, pp.
121–127, 2007.
[75] S. C. Bergheanu, A. Van Tol, G. M. Dallinga-Thie et al., “Eﬀect
of rosuvastatin versus atorvastatin treatment on paraoxonase-
1 activity in men with established cardiovascular disease and a
low HDL-cholesterol,” Current Medical Research and Opinion,
vol. 23, no. 9, pp. 2235–2240, 2007.
[76] H.Mirdamadi,F.Sztanek,Z.Derdak,I.Seres,M.Harangi,and
G. Paragh, “The human paraoxonase-1 phenotype modiﬁes
the eﬀect of statins on paraoxonase activity and lipid param-
eters,” British Journal of Clinical Pharmacology, vol. 66, no. 3,
pp. 366–374, 2008.
[77] M.Shiner,B.Fuhrman,andM.Aviram,“Macrophageparaox-
onase 2 (PON2) expression is up-regulated by pomegranate
juice phenolic anti-oxidants via PPARγ and AP-1 pathway
activation,” Atherosclerosis, vol. 195, no. 2, pp. 313–321, 2007.
[ 7 8 ]J .K h a t e e b ,A .G a n t m a n ,A .J .K r e i t e n b e r g ,M .A v i r a m ,a n dB .
Fuhrman, “Paraoxonase 1 (PON1) expression in hepatocytes
is upregulated by pomegranate polyphenols: a rolefor PPAR-γ
pathway,” Atherosclerosis, vol. 208, no. 1, pp. 119–125, 2010.
[ 7 9 ]J .M a r s i l l a c h ,J .C a m p s ,N .F e r r ´ e et al., “Paraoxonase-1 is
related to inﬂammation, ﬁbrosis and PPAR delta in experi-
mental liver disease,” BMC Gastroenterology, vol. 9, article 3,
2009.
[80] A. J. Lusis, “Atherosclerosis,” Nature, vol. 407, no. 6801, pp.
233–241, 2000.
[81] R.Ross,“Thepathogenesisofatherosclerosis:aperspectivefor
the 1990s,” Nature, vol. 362, no. 6423, pp. 801–809, 1993.
[82] B. Mackness, D. Hine, Y. Liu, M. Mastorikou, and M. Mack-
ness, “Paraoxonase-1 inhibits oxidised LDL-induced MCP-1
production by endothelial cells,” Biochemical and Biophysical
Research Communications, vol. 318, no. 3, pp. 680–683, 2004.
[83] A. Rull, R. Garc´ ıa, L. Fern´ andez-Sender et al., “The role of
combined assessment of defense against oxidative stress and
inﬂammation in the evaluation of peripheral arterial disease,”
Current Molecular Medicine, vol. 11, no. 6, pp. 453–464, 2011.
[84] A. Rull, J. Camps, C. Alonso-Villaverde, and J. Joven, “Insulin
resistance, inﬂammation, and obesity: role of monocyte
chemoattractant protein-1 (orCCL2) in the regulation of
metabolism,” Mediators of Inﬂammation, vol. 2010, Article ID
326580, 2010.
[85] J. X. Rong, J. W. Berman, M. B. Taubman, and E. A. Fisher,
“Lysophosphatidylcholine stimulates monocyte chemoattrac-
tant protein-1 gene expression in rat aortic smooth muscle
cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol.
22, no. 10, pp. 1617–1623, 2002.
[ 8 6 ]A .R u l l ,R .B e l t r ´ an-Deb´ o n ,G .A r a g o n ` es et al., “Expression of
cytokinegenesintheaortaisalteredbythedeﬁciencyinMCP-
1: eﬀect of a high-fat, high-cholesterol diet,” Cytokine, vol. 50,
no. 2, pp. 121–128, 2010.
[87] C. H. Hsing, W. Chou, J. J. Wang, H. W. Chen, and C.
H. Yeh, “Propofol increases bone morphogenetic protein-7
and decreases oxidative stress in sepsis-induced acute kidney
injury,” Nephrology Dialysis Transplantation,v o l .2 6 ,n o .4 ,p p .
1162–1172, 2011.
[88] C. C. Chuang, K. Mart´ ınez, and G. Xie et al, “Quercetin is
equallyormoreeﬀectivethanresveratrolinattenuatingtumor
necrosis factor alpha-mediated inﬂammation and insulin
resistance in primary human adipocytes,” American Journal of
Clinical Nutrition, vol. 92, pp. 1511–1521, 2010.
[89] D. Wang, A. Haile, and L. C. Jones, “Rosiglitazone-induced
adipogenesis in a bone marrow mesenchymal stem cell line—
biomed 2011,” Biomedical Sciences Instrumentation, vol. 47,
pp. 213–221, 2011.
[90] W. M. Wang, H. Chen, F. Zhong, Y. Lu, L. Han, and N. Chen,
“Inhibitory eﬀects of rosiglitazone on lipopolysaccharide-
induced inﬂammation in a murine model and HK-2 cells,”
American Journal of Nephrology, vol. 34, no. 2, pp. 152–162,
2011.
[91] T. Matsumura, H. Kinoshita, N. Ishii et al., “Telmisartan
exerts antiatherosclerotic eﬀects by activating peroxisome
proliferator-activated receptor-γ in macrophages,” Arterioscle-
rosis, Thrombosis, and Vascular Biology,v o l .3 1 ,n o .6 ,p p .
1268–1275, 2011.
[ 9 2 ]M .E .M a r k e t o u ,J .E .K o n t a r a k i ,N .A .T s a k o u n t a k i se ta l . ,
“Diﬀerential eﬀect of telmisartan and amlodipine on mono-
cyte chemoattractant protein-1 and peroxisome proliferator-
activated receptor-gamma gene expression in peripheral
monocytes in patients with essential hypertension,” American
Journal of Cardiology, vol. 107, no. 1, pp. 59–63, 2011.